Latest news with #Isotretinoin
India Today
26-05-2025
- Business
- India Today
Stocks to watch on May 26: Hyundai, Swiggy, Eternal, Paytm, NTPC Green
The stock market will start the new week on Monday after closing last week with gains. This was helped by hopes around US-China trade talks, even as foreign investor selling continued to be a companies will be in focus due to their earnings announcements, major updates, or new developments as investors hope for Dalal Street to mainatin its winning run. Q4 RESULTS TODAYA number of companies will release their quarterly results on May 26. These include Aurobindo Pharma, Brainbees Solutions (FirstCry), KEC International, Nazara Technologies, Akums Drugs and Pharmaceuticals, Awfis Space Solutions, Blue Dart Express, General Insurance Corporation of India, Infibeam Avenues, Olectra Greentech, Apeejay Surrendra Park Hotels, Shilpa Medicare, Talbros Automotive Components, and Tracxn Technologies. These results will help investors understand how these companies have performed NTPC GREEN, SWIGGY Hyundai Motor India, NTPC Green Energy, Swiggy, and Waaree Energies will be added to the FTSE global equity indices under the largecap category. This move is expected to bring more attention to these companies and could lead to increased investor interest. Meanwhile, ITC Hotels, which was recently spun off from ITC, will exit the largecap One 97 Communications, the parent company of Paytm, received a major relief from the Supreme Court. The court has stayed proceedings related to a show cause notice issued to its subsidiary First Games notice, sent by the Directorate General of GST Intelligence on April 28, 2025, demanded Rs 5,712 crore in taxes, interest, and penalties for the period between January 2018 and March (ZOMATO)Eternal (Zomato) may see outflows of around $840 million. This is due to a likely reduction in its weightage by global index providers FTSE Russell and MSCI. The change comes after the company's foreign ownership limit was reduced from 100% to 49.5%, as reported by CNBC TV-18 citing IIFL Capital STEELJSW Steel reported a 16% rise in consolidated net profit for the fourth quarter, coming in at Rs 1,503 crore, compared to Rs 1,299 crore in the same quarter last year. This shows a steady performance by the steel major despite global LEYLAND Ashok Leyland reported a 38% year-on-year increase in its Q4 standalone net profit, reaching Rs 1,246 crore compared to Rs 900 crore in the same period last year. This growth reflects strong demand and improved performance in the commercial vehicle LIFESCIENCES Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) for its Isotretinoin capsules. These are used to treat severe nodular acne. The product will be made at the company's plant in Moraiya, near PHARMA Sun Pharma has announced a new investment of up to $25 million in US-based biopharma company Pharmazz Inc. With this, its total stake in the firm will rise to around 22.7% on a fully diluted basis. The move is part of Sun Pharma's efforts to expand its global presence in the speciality drug Havells India will increase its cable manufacturing capacity at its Alwar facility by 0.25 lakh km, taking the total to 41.45 lakh km per year. This will be done with an investment of Rs 340 crore, which will be funded through internal cash reserves. The new capacity is expected to be ready by September NIBE has received an export order worth $17.52 million (around Rs 150.62 crore) from a leading defence technology company in Israel. The order is for the manufacturing and supply of Universal Rocket Launchers, which highlights the company's growing reach in the global defence sector. advertisement
Business Standard
26-05-2025
- Business
- Business Standard
Zydus Life gets USFDA nod for Isotretinoin capsules
Zydus Lifesciences announced that it has received a final approval for Isotretinoin capsules from US Food and Drug Administration (USFDA). The approved drug is the generic equivalent of the reference listed drug Absorica capsules, available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg strengths. Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne. The product will be manufactured at the Groups facility in Moraiya, Ahmedabad. According to IQVIA MAT 2025, Isotretinoin capsules had annual sales of $115.4 million in the United States. As of 31st March 2025, the group now has received a total of 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a global life sciences company engaged in the discovery, development, manufacturing, and marketing of a wide range of healthcare therapies. The companys consolidated net profit fell 1% to Rs 1,170.90 crore despite of 17.2% increase in net sales to Rs 6290.20 crore in Q4 FY25 over Q4 FY24. The counter rose 0.45% to settle at Rs 908 on Friday, 23 May 2025.
Business Upturn
26-05-2025
- Business
- Business Upturn
Stocks to watch today: Paytm, Eternal, Zydus Life, NIBE, Havells India, NTPC, Gravita India, Ramco Cements, Lloyds Metals, JSW Steel, Cartrade Tech and more
Markets are expected to open with several stocks in focus on May 26 as major companies report their earnings, announce dividends, or are impacted by regulatory and strategic developments. Here's a detailed roundup of stocks to watch and the key highlights that could impact trading today. NTPC, JSW Steel, JK Cement report Q4 earnings NTPC reported a 21.7% year-on-year (YoY) jump in consolidated net profit at Rs 7,897.1 crore for Q4 FY25, compared to Rs 6,490 crore in the same period last year. Revenue rose 4.6% to Rs 49,833.7 crore. The board recommended a final dividend of Rs 3.35 per share. However, overall numbers were below consensus estimates, and commissioning targets were missed. JSW Steel posted a 13.5% rise in Q4 net profit to Rs 1,501 crore, even as revenue declined 3.1% to Rs 44,819 crore. The board declared a final dividend of Rs 2.80 per share. Standalone EBITDA per tonne was in-line, while losses in overseas operations declined. JK Cement saw a 64% YoY surge in profit at Rs 360.4 crore and a 15.3% increase in revenue to Rs 3,581.2 crore. The board recommended a dividend of Rs 15 per share. EBITDA came in above analyst estimates, with grey cement net sales realisations up 3% quarter-on-quarter. Other companies such as Ashoka Buildcon (EBITDA up 22.3%, margin at 28.9%), GNFC (EBITDA up 65.5%, margin at 11.7%), Finolex Industries, HBL Engineering, and Lux Industries reported mixed Q4 performances. Lux reported margin compression to 8.9% and revenue decline of 15.6% YoY. Ganesha Ecosphere Q4 performance Ganesha Ecosphere reported consolidated revenue of Rs 344.4 crore in Q4 FY25, up from Rs 305.5 crore YoY. EBITDA rose to Rs 51.1 crore, while PAT came in at Rs 23.8 crore. Production volume rose to 38,790 MT. However, EBITDA/ton dropped to Rs 13,200 from Rs 17,000. For FY25, the company achieved Rs 200 crore EBITDA and Rs 100 crore PAT. Capacity utilization in the standalone business was at 99%. Key corporate developments Paytm: SC has stayed the Rs 5,712 crore GST notice against First Games. Eternal (Zomato): MSCI and FTSE reduced weightage due to cut in foreign ownership limit. Zydus Lifesciences: Received final US FDA approval for Isotretinoin capsules. NIBE: Won a Rs 150.6 crore export order from an Israeli defence tech company. Havells: To invest Rs 340 crore to boost cable capacity at Alwar by September 2026. Biocon: Received UK MHRA approval for YESINTEK, biosimilar Ustekinumab. GE Vernova: Posted better-than-expected performance with margin expansion of 973 bps YoY. Divi's Labs: Signed supply pact with global pharma major, involving Rs 650–750 crore capex. Narayana Health: Revenue grew 18% YoY; margin improved to 26.1%. Jyoti CNC: Margin at multi-quarter high, EBITDA up 33% YoY. AB Fashion: Margin expanded to 17.2% vs 6.2% YoY; revenue up 9%. Anupam Rasayan: EBITDA up 55.7%; margin at 28.86%. HCG: EBITDA up 15%, revenue grew 18.3%. Allcargo: EBITDA rose 16.5%, revenue up 18%. Q4 and Regulatory updates Glenmark: Missed FY25 guidance, US business revenue declined. Afcons Infra: Q4 muted; FY25 revenue missed guidance. DRL: Received Form 482 from US FDA with two observations for CTO-5 unit. Finolex: Revenue fell 5%, margin dropped to 14.62% from 16.9%. HBL Engineering: EBITDA declined 40.7%, margin dropped to 16.94%. Balkrishna Industries: EBITDA declined 9.9%, margin at 22.29%. Kolte Patil: Q4 sales value fell 7%, realisations down 6% QoQ. Indigo Paints: Gross margin dropped to 46.8%, revenue up 0.7%. Updater Services: EBITDA down 12%, margin fell to 5%. Dreamfolks: Margin at 6.31%, EBITDA down 19% YoY. Bulk deals on May 24 First Sentier acquired shares in Cartrade Tech, Motilal Oswal PMS bought into Gravita India, and Nippon India Mutual Fund picked up 19.5 lakh shares of Ramco Cements. Bandhan Mutual Fund acquired a stake in Pondy Oxides & Chemicals. Other stock updates Stocks like Archean Chemical, Lloyds Metals, and Pearl Global are trading ex-dividend today. Maple Infrastructure Trust trades ex-date for income distribution. Chambal Fertilisers, Hindustan Copper, Dixon Technologies, Manappuram Finance, RBL Bank, and Titagarh Rail Systems remain in the F&O ban list. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Daily Mirror
16-05-2025
- Entertainment
- Daily Mirror
MAFS star had to make heartbreaking choice after discovering 7 month pregnancy
Laura Vaughan first rose to fame on Married At First Sight UK on the 2023 series but the reality star has since opened up about the her recent heartbreaking ordeal A Married At First Sight star was devastated after discovering she was seven months pregnant as she had to make a heartbreaking choice. Laura Vaughan rose to fame on the show but has dealt with a difficult situation behind the scenes. Laura underwent a medial abortion after she unexpectedly found out she was seven months into a surprise pregnancy. The 35-year-old underwent the procedure after finding she had unknowingly been putting the unborn foetus at risk of severe birth defects by taking medication to treat her acne. The procedure happened in 2016 when she was 26-years-old. Laura has now opened up about what she went through nine years ago. Speaking to The Sun, Laura said: "It was very difficult because I went from not thinking I was pregnant to being seven months pregnant to then having a very prolonged abortion and where I was so far gone. Then, when I got home from the procedure, my milk came in, which, as you can imagine, was just really hard to deal with. I hunkered down at home for weeks and didn't talk to anyone." Laura was shocked when she found that a pregnancy test revealed that she was expecting, but she certainly didn't expect it when she went to the doctors and they said she was in her third trimester. The TV star said she had experiencing bloating and missed periods but at the time thought this was down to a "ruptured cyst". She went to a doctor to discuss her symptoms but looking at medical records, they thought she had a ruptured cyst and polycystic ovary syndrome. Laura was then meant to go for a scan but kept forgetting to book it in. Laura was still able to fit into her clothes and just thought she was bloated when she decided to do a test. She said her stomach popped when she took a test and found out she was pregnant. Soon after finding out she was pregnant, Laura was then told that the acne drug she had been taking, isotretinoin, can cause birth defects. Consultant dermatologist Dr Jonathan Kentley said: "Isotretinoin [also known as Roaccutane] is the most effective treatment we have for severe acne and, for many patients, it is a cure for their distressing condition. "Whilst the medication is usually well tolerated, it must be prescribed under the expert supervision of a consultant dermatologist as there is a potential for side effects. Importantly, isotretinoin is extremely harmful to the unborn foetus, leading to birth defects." Laura went to hospital for the medical abortion and was meant to be in and out in a day and a half but ended up being there for nearly a week. She said she went in for the procedure and they couldn't get her to go into full labour but she was in "agony". "It impacted me so heavily. All of it," she said. Laura is now in a long term relationship with her boyfriend who she met after appearing on MAFS in 2023.
USA Today
11-04-2025
- Health
- USA Today
Before starting isotretinoin, here's what dermatologists need you to consider
Before starting isotretinoin, here's what dermatologists need you to consider Show Caption Hide Caption Carcinogenic chemical found in popular acne creams The safety of skin care has come under scrutiny as elevated levels of the carcinogen benzene have been found in acne creams. unbranded - Newsworthy If you're someone who's experienced recurring bouts of cystic acne, you'll know there's no one-size-fits-all approach to keeping acne flares at bay. Clearing your skin can feel like a bit of a waiting game, and if you've cycled through rounds of hormonal therapies, oral antibiotics and topical retinoids to no avail, you've likely considered isotretinoin as a possible acne treatment. Isotretinoin is a powerful oral retinoid that can be prescribed to treat resistant cystic acne. The medication's acne-fighting benefits have been backed by science for decades, but it's important to be aware of a few serious risks. Here's what dermatologists need you to know. What is isotretinoin? What is Accutane? Isotretinoin is a potent derivative of vitamin A that shrinks oil glands in the face, chest, back, shoulders and upper arms, says Dr. Richard Antaya, director of pediatric dermatology for Yale Medicine. The medication was first approved by the U.S. Food & Drug Administration in 1982 under its original brand name, Accutane. Accutane itself isn't actually sold in the U.S. anymore, and has since been replaced by different generic formulations of isotretinoin, explains Antaya. Isotretinoin lowers sebum production in the skin; sebum is a waxy, oily substance that's meant to protect the skin from moisture loss. The sebaceous glands that live under our hair follicles secrete sebum. When we produce too much sebum, and the sebaceous glands become infected, acne may develop, says Dr. Andrew Wong, a primary care physician in Westport, Connecticut, and Fairfield County regional medical director for Hartford Healthcare. By removing the underlying mechanism of acne (sebum production), isotretinoin unclogs pores and quells skin inflammation. 'I always tell my patients, decreasing the oil (or sebum) takes the wind out of the sails of acne,' says Antaya. The results are palpable: With just one course of isotretinoin, the majority of patients will see a great improvement, and in many cases, a near-complete clearing of acne, Antaya says. How isotretinoin works, plus who is a good candidate? Isotretinoin could be a great option for those in search of a long-lasting solution to their cystic acne. That said, the medication does have severe potential side effects, which is why it's not for everyone. There's a few reasons why a dermatologist may prescribe isotretinoin: Your acne is persistent. You've tried multiple treatments for acne—from topical retinoids to benzoyl peroxide to oral antibiotics—and your acne still isn't clearing up. You've tried multiple treatments for acne—from topical retinoids to benzoyl peroxide to oral antibiotics—and your acne still isn't clearing up. You have severe, nodular cystic acne. Topical medication is rarely, if ever, effective for treating nodular cystic acne. If you haven't responded well to other oral acne treatments, including oral antibiotics or hormonal therapies, that's when a dermatologist may consider prescribing isotretinoin, Antaya says. Topical medication is rarely, if ever, effective for treating nodular cystic acne. If you haven't responded well to other oral acne treatments, including oral antibiotics or hormonal therapies, that's when a dermatologist may consider prescribing isotretinoin, Antaya says. You have severe acne scarring: Severe acne can be disfiguring, leaving permanent scars, says Wong. Isotretinoin can't get rid of scarring, but as your skin clears, it may improve the appearance of scars, and help prevent new ones from forming. More on cystic acne: Cystic acne can cause pain, shame and lasting scars. Here's what causes it. What are the risks of isotretinoin? The decision to start isotretinoin isn't one that should be taken lightly—it's a medicine that carries significant risks. Isotretinoin shrinks the oil glands and thins the epidermal barrier, which could cause dryness of the skin, lips and nose. Other potential side effects include joint and muscle pain, eye irritation, elevated blood fat levels and in rare cases, liver damage. Isotretinoin is known to cause severe birth defects and miscarriages in people who are pregnant, says Wong. For this reason, isotretinoin isn't the kind of medication that can be prescribed on a yearly basis; it has to be renewed every month. 'We have strict safeguards in place to make sure we get positive feedback that someone is doing well with the medicine, and that they performed a pregnancy test during that month,' Wong explains. Patients must enroll and adhere to the iPLEDGE program, an FDA-mandated registry to help prevent pregnancy in patients taking isotretinoin. Isotretinoin has also been associated with depression and suicidal thoughts, though the American Academy of Dermatology says there currently isn't enough evidence to determine a clear link. Patients will be screened for possible signs of depression or suicidal ideation before isotretinoin is prescribed. 'So, I strongly recommend that if an acne patient suffers from depression, the dermatologist works with the mental health professional to ensure the patient can undergo a course of isotretinoin,' says Antaya. In case you missed: How do antibiotics work, what happens to your body when you take them? We've got answers. Can isotretinoin cure acne? If your dermatologist has determined you're a good candidate for isotretinoin, know that it could take two to three months before you start to see a significant improvement in your acne, and four to six months (or potentially longer!) for it to clear—though the results are long-lasting. After completing a single course of isotretinoin, around 85% of patients will experience a long-term clearing of skin, says Wong. Today, isotretinoin still stands to be the most clinically effective treatment for severe acne. 'Even though isotretinoin has been available for over 40 years, if you ask most dermatologists, we will still list (isotretinoin) as one of our favorite medications, because it is consistently effective and therefore provides significant benefit, both physically and emotionally, to our patients,' Antaya says.
